Search results for: Health Policy and Regulation
Filter search results
Around the World in HTAs: United States – Making HTA Great Again
11 June 2024
A primer on US health care The US’s health care system is notable for its contrast with that of other high-income countries. Most notably, the US lacks universal health coverage….
Global equity in the shadow of US pricing reform: Access by bargaining power? | Insights from a WHS side event
22 October 2026
…implications of MFN continue to unfold, drugmakers and policymakers are left to manage significant uncertainty around the policy’s enactment, the consequences for countries that fall within the proposed price index and…
The cost of inaction on LDL cholesterol
24 June 2026
…for health systems is straightforward: given the substantial but avoidable health and economic burdens of ASCVD, there is a clear imperative for better prevention and management of elevated LDL-C. Where…
Around the World in HTAs: Australia – The lucky country’s waiting game
5 October 2026
…and an income-based levy, and covers most costs of public hospital treatment and subsidised out-of-hospital medical services. Around half of Australians also hold private health insurance, largely to access private hospital…
Understanding the preferences of people with acute leukemia for different health outcomes
25 September 2025
…studies and health policy decisions take patient priorities into account. This research paper, Understanding the preferences of people with acute leukemia for different health outcomes, was commissioned and funded by the Acute Leukemia…
Valuing patient and carer time in HTA: equity and opportunity cost
15 May 2026
…carer time are inputs to healthcare just as much as physician and nursing time. As such, trade-offs between time and health are no different from trade-offs between money and health….
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…and involve patients and their healthcare professionals to ensure that the development and implementation of LA therapies align with patient needs, health system improvements, and societal or economic goals. The…
The Faces of Regulation: Profit and Price Regulation of the UK Pharmaceutical Industry after the 1998 Competition Act
1 May 2006
…of regulation between the Department of Health as buyer and of the OFT in its role as the agent of general competition law. The paper does not address the OFT…
The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?
22 May 2020
The colossal health and economic shock caused by COVID-19 has highlighted the vital role that the public and private sectors play in finding health solutions and producing them in massive…